Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Ltd) has received a Warning Letter from the US Food and Drug Administration (US FDA) following an inspection conducted at its Finished Dosage Formulations (FDF Unit-I) facility in Nacharam, Hyderabad. The company is addressing the observations with corrective and preventive actions as per regulatory guidelines.
Show moreStay Ahead – Explore Now! Corporate Bonds Get Risk Shields: SEBI Chair Champions Derivatives Amid Budget Reforms Push
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
